Glucocorticoids are the mainstay of CAH treatment with the double aim of preventing adrenal insufficiency and suppressing androgen excess through a direct negative feedback to the pituitary adrenocorticotropic hormone (ACTH) secretion [1, 3]. The gene discussed is POMC; the disease is congenital adrenal hyperplasia.